Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Novel triazines as potent and selective phosphodiesterase 10A inhibitors.

Malamas MS, Stange H, Schindler R, Lankau HJ, Grunwald C, Langen B, Egerland U, Hage T, Ni Y, Erdei J, Fan KY, Parris K, Marquis KL, Grauer S, Brennan J, Navarra R, Graf R, Harrison BL, Robichaud A, Kronbach T, Pangalos MN, Brandon NJ, Hoefgen N.

Bioorg Med Chem Lett. 2012 Sep 15;22(18):5876-84. doi: 10.1016/j.bmcl.2012.07.076. Epub 2012 Jul 31.

PMID:
22902656
2.

Highly potent, selective, and orally active phosphodiesterase 10A inhibitors.

Malamas MS, Ni Y, Erdei J, Stange H, Schindler R, Lankau HJ, Grunwald C, Fan KY, Parris K, Langen B, Egerland U, Hage T, Marquis KL, Grauer S, Brennan J, Navarra R, Graf R, Harrison BL, Robichaud A, Kronbach T, Pangalos MN, Hoefgen N, Brandon NJ.

J Med Chem. 2011 Nov 10;54(21):7621-38. doi: 10.1021/jm2009138. Epub 2011 Oct 11.

PMID:
21988093
3.

Discovery of imidazo[1,5-a]pyrido[3,2-e]pyrazines as a new class of phosphodiesterase 10A inhibitiors.

Höfgen N, Stange H, Schindler R, Lankau HJ, Grunwald C, Langen B, Egerland U, Tremmel P, Pangalos MN, Marquis KL, Hage T, Harrison BL, Malamas MS, Brandon NJ, Kronbach T.

J Med Chem. 2010 Jun 10;53(11):4399-411. doi: 10.1021/jm1002793.

PMID:
20450197
4.
5.

Refolding and purification of recombinant human PDE7A expressed in Escherichia coli as inclusion bodies.

Richter W, Hermsdorf T, Kronbach T, Dettmer D.

Protein Expr Purif. 2002 Jun;25(1):138-48.

PMID:
12071709
6.

New metabolic pathways of alpha-lipoic acid.

Schupke H, Hempel R, Peter G, Hermann R, Wessel K, Engel J, Kronbach T.

Drug Metab Dispos. 2001 Jun;29(6):855-62.

PMID:
11353754
7.

Identification of inhibitor binding sites of the cAMP-specific phosphodiesterase 4.

Richter W, Unciuleac L, Hermsdorf T, Kronbach T, Dettmer D.

Cell Signal. 2001 Apr;13(4):287-97.

PMID:
11306246
8.

Identification of substrate specificity determinants in human cAMP-specific phosphodiesterase 4A by single-point mutagenesis.

Richter W, Unciuleac L, Hermsdorf T, Kronbach T, Dettmer D.

Cell Signal. 2001 Mar;13(3):159-67.

PMID:
11282454
9.

Refolding, purification, and characterization of human recombinant PDE4A constructs expressed in Escherichia coli.

Richter W, Hermsdorf T, Lilie H, Egerland U, Rudolph R, Kronbach T, Dettmer D.

Protein Expr Purif. 2000 Aug;19(3):375-83.

PMID:
10910728
10.

Disposition and metabolism of cetrorelix, a potent luteinizing hormone-releasing hormone antagonist, in rats and dogs.

Schwahn M, Schupke H, Gasparic A, Krone D, Peter G, Hempel R, Kronbach T, Locher M, Jahn W, Engel J.

Drug Metab Dispos. 2000 Jan;28(1):10-20.

PMID:
10611134
11.

Metabolism of retigabine (D-23129), a novel anticonvulsant.

Hempel R, Schupke H, McNeilly PJ, Heinecke K, Kronbach C, Grunwald C, Zimmermann G, Griesinger C, Engel J, Kronbach T.

Drug Metab Dispos. 1999 May;27(5):613-22.

PMID:
10220491
12.

Retigabine N-glucuronidation and its potential role in enterohepatic circulation.

Hiller A, Nguyen N, Strassburg CP, Li Q, Jainta H, Pechstein B, Ruus P, Engel J, Tukey RH, Kronbach T.

Drug Metab Dispos. 1999 May;27(5):605-12.

PMID:
10220490
14.

Purification and characterization of recombinant-expressed cytochrome P450 2C3 from Escherichia coli: 2C3 encodes the 6 beta-hydroxylase deficient form of P450 3b.

Richardson TH, Hsu MH, Kronbach T, Barnes HJ, Chan G, Waterman MR, Kemper B, Johnson EF.

Arch Biochem Biophys. 1993 Jan;300(1):510-6.

PMID:
8380971
15.

Analysis of the catalytic specificity of cytochrome P450 enzymes through site-directed mutagenesis.

Johnson EF, Kronbach T, Hsu MH.

FASEB J. 1992 Jan 6;6(2):700-5. Review.

PMID:
1537459
16.

Properties of expressed and native flavin-containing monooxygenases: evidence of multiple forms in rabbit liver and lung.

Lawton MP, Kronbach T, Johnson EF, Philpot RM.

Mol Pharmacol. 1991 Nov;40(5):692-8.

PMID:
1944240
17.

A hypervariable region of P450IIC5 confers progesterone 21-hydroxylase activity to P450IIC1.

Kronbach T, Kemper B, Johnson EF.

Biochemistry. 1991 Jun 25;30(25):6097-102.

PMID:
2059619
18.
19.

Bufuralol, dextromethorphan, and debrisoquine as prototype substrates for human P450IID6.

Kronbach T.

Methods Enzymol. 1991;206:509-17. No abstract available.

PMID:
1686064
20.

Hybrid cytochromes P-450 identify a substrate binding domain in P-450IIC5 and P-450IIC4.

Kronbach T, Larabee TM, Johnson EF.

Proc Natl Acad Sci U S A. 1989 Nov;86(21):8262-5.

21.

Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4.

Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA.

Mol Pharmacol. 1989 Jul;36(1):89-96.

PMID:
2787473
22.

In vitro characterization of the human cytochrome P-450 involved in polymorphic oxidation of propafenone.

Kroemer HK, Mikus G, Kronbach T, Meyer UA, Eichelbaum M.

Clin Pharmacol Ther. 1989 Jan;45(1):28-33.

PMID:
2910635
27.
28.

Stereo- and regioselectivity of hepatic oxidation in man--effect of the debrisoquine/sparteine phenotype on bufuralol hydroxylation.

Dayer P, Leemann T, Küpfer A, Kronbach T, Meyer UA.

Eur J Clin Pharmacol. 1986;31(3):313-8.

PMID:
2878813
29.

Assay of mephenytoin metabolism in human liver microsomes by high-performance liquid chromatography.

Meier UT, Kronbach T, Meyer UA.

Anal Biochem. 1985 Dec;151(2):286-91.

PMID:
4096368
30.

Mephenytoin hydroxylation polymorphism: characterization of the enzymatic deficiency in liver microsomes of poor metabolizers phenotyped in vivo.

Meier UT, Dayer P, Malè PJ, Kronbach T, Meyer UA.

Clin Pharmacol Ther. 1985 Nov;38(5):488-94.

PMID:
4053486
32.
33.
34.

Supplemental Content

Loading ...
Support Center